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The ability to generate methotrexate-resistant (MTX')' hematopoietic cells via
gene transfer techniques would have a number of important implications for
both basic gene transfer studies in hematopoietic cells and eventual clinical
applications of the gene transfer technology . In the case of general studies
involving the transfer of genes into stem cells in vitro and the subsequent
engraftment of recipients with the transduced cells, a major limitation to the
wide application of the technique is the need for very-high-titer virus-producing
cell lines in order to obtain efficient gene transfer (1) . In an attempt to increase
the efficiency of gene therapy, several groups have explored the use of selective
schemes in vitro to increase the percentage of transduced stem cells before
transplantation (2-4) . Thus far, the neo phosphotransferase (neo) gene (5) has
been used in conjunction with the drug G418 for these studies . While this
selection is a powerful one in vitro, it is unlikely that it could be applied in vivo,
due to the dose-limiting toxicity of G418 in other organs . The introduction of
methotrexate resistance into bone marrow stem cells, however, may well enable
the selection of transduced hematopoietic cells in vivo, and even make possible
the transplantation of sublethally irradiated or untreated recipients. In addition
to potential use in obtaining efficient engraftment with transduced cells, the
generation of recipients engrafted with drug-resistant bone marrow may also
facilitate the development of more aggressive chemotherapeutic regimens that
otherwise might lead to lethal bone marrow toxicity .
As a first step towards the development of a general method for generating
MTXr bone marrow cells at high efficiency, we have constructed and character-
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￿
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210
￿
J . Exp . MED . C The Rockefeller University Press - 0022-1007/87/07/0210/09 $2 .00
Volume 166 July 1987 210-218WILLIAMS ET AL.
￿
211
ized the properties of recombinant retroviruses encoding a dihydrofolate reduc-
tase (DHFR) enzyme that is highly resistant to methotrexate (DHFR') (6) . In this
report we describe some of the properties of the viruses in vitro, and present
data that indicates that mice engrafted with bone marrow cells previously infected
with the DHFR` retroviruses are protected from doses of MTX that are lethal
when administered to transplant recipients engrafted with uninfected bone
marrow.
Materials and Methods
Infection ofBone Marrow Cells, Transplantation, and MTX TreatmentofRecipients.
￿
The
infection of bone marrow cells in vitro with recombinant viruses and transplantation of
the cellsin lethally irradiated recipients was performed as described (1), except that freshly
explanted CBA/J male bone marrow was used for infection and CBA/J males served as
recipients. CBA/J recipients were irradiated with a split dose of 14 Gy before transplan-
tation. Bone marrow cellswere infected with neo gene-carrying virus (1), and transplanted
to yield control mice. Cell counts and CFU-S (colony-forming units of spleen cells)
determinations were made to ascertain that equal numbers of cells and CFU-S were
transplanted into each group of mice.
2 d after transplantation, the recipients were subjected to a thrice-weekly schedule of
intraperitoneal MTX administration. This consisted of 4 mg/kg in the first week, followed
by 10 mg/kg for the following 7 wk. The schedule was shown in preliminary experiments
done for previous studies to result in the death of all recipients transplanted with
uninfectedbone marrow cells. At intervals after the transplant, peripheral hematocrit and
total blood counts with differentials were performed on tail vein bleeds. In addition,
animals were sacrificed, and both bone marrow cells (provided from the hind limbs of all
animals) and spleen cells from individual animals were analyzed for cellular and progenitor
content (colony-forming units of granulocytes and macrophages [CFU-GM], and burst-
forming units of erythroid cells [BFU-E]) (see below), and for the presence of proviral
DNA sequences.
Bone Marrow Progenitor Assays.
￿
Bone marrow was isolated as previously described
from the hind limbs of animals (1), pooled, and counted. 2 X 105 bone marrow cells/ml
were plated in MEM/a-methylcellulose, 24% FCS, 1 % BSA (Boehringer Mannheim
Biochemicals, Indianapolis, IN), 10-5 M 2-ME (Sigma Chemical Co., St. Louis, MO), 1
penicillin/streptomycin, and L-glutamine with 10% L cell supernatant as colony-stimulat-
ing factor for granulocytic colonies (7) or 5% pokeweed mitogen-stimulated spleen-
conditioned media as burst-promoting activity with 2 U/ml erythropoietin (Connaught
Laboratories, Ltd., Willowdale, Canada) for erythroid colonies (8). Progenitor cocktails
were plated in 1-ml culture (in triplicates) in 10 X 35-mm tissue culture plates (Lux; Miles
Scientific, Naperville, IL) and placed in 5% C02 at 37 ° C. Colonies were counted (>50
cells) at day 10 of cultures.
Southern Blot Analysis.
￿
High-molecular-weight cellular DNA was extracted, digested
with Eco RI or Xba I (New England Biolabs, Beverly, MA) and electrophoresed through
a 1 % agarose gel. The DNA was transferred to a Zetabind filter (AMF/Voit, Meriden,
CT) and hybridized to "P-labeled Hind III-Bgl II DHFR fragment isolated from PSV2
DHFR as previously described. Filters were washed as described by the manufacturer and
exposed to x-ray films at -70°C in the presence of intensifying screens.
Results
Generation of Cell Lines Producing High Titers of Virus Encoding MTX Resis-
tance. The source of DHFR-coding sequences used in the construction of a
recombinant retroviral genome encoding MTX resistance was the plasmid
pR400-12 (kindly provided by Genentech, Inc., South San Francisco, CA). This
plasmid carries DNA sequences that encode a mutant murine DHFR enzyme21 2
￿
GENERATION OF METHOTREXATE-RESISTANT BONE MARROW
Zip DHFR R
￿
FIGURE 1 .
￿
Map of Zip-DHFR'. Se-
quences include the Moloney long
terminal repeats and sequences nec
xbo
￿
BAM
￿
xbo
￿
essary for the efficient encapsidation
of the viral genome (designated 4).
The 5' splice site used in the gener-
ation of the Moloney murine leu-
kemia virus env mRNA is designated
5'ss, and the 3' splice acceptor is
designated 3'ss. Restriction sites are
as shown, includinga unique Xho I cloning site 3' of the selectable marker. Thetotalsize of the Zip-
DHFR'construct is 2.7 kb. Note that Xba I cleaves once in each long terminal repeat, and that Eco
RI does notcleave the provirus.
(DHFR') that has 1/270 the binding affinity for MTX that the wild type enzyme
possesses. A 660 by Fnu 4 HI-Bgl II DNA segment encompassing the DHFR
coding sequence was isolated from pR400-12 and inserted into the Bam HI
cloning site of the retrovirus vector pZIPNeoSV(X) (9). Subsequently, a portion
ofSV(X) vector sequences (including pBR322ori, SV40ori, and neo sequences)
was deleted from the construct by cleavage of the plasmid with Xho I, removal
ofthe smaller Xho I fragment, and recirculation ofthe plasmid sequences. The
structure of the resulting plasmid, termed pZIP-DHFR' is shown in Fig. 1.
In an attempt to generate cell lines producing titers of DHFR virus suitable
for the infection of bone marrow cells, conditions were established so that
multiple Zip-DHFR' proviral copies could be introduced into the 4'2 cells. First,
the Zip-DHFR' construct was introduced by DNA transfection into ¢AM cells
(10) to generate virus with amphotropic host range. Selections of stable trans-
formants in the presence of0.25,um MTX yielded cell lines that produced 102-
10' MTX' colonies/ml when assayed on 3T3 cells cultured in 0.25 Am MTX
and dialyzed calf serum (8-10 kD cutoff vs. PBS). While 4,2 cells are resistant to
superinfection with ecotropic virus, theycan bereadily infected withamphotropic
virus. Accordingly, irradiated (14 Gy) ¢AM cells producing Zip-DHFR' virus
were cocultured with ~2 cells to achieve a highly efficient infection. After
selection of infected ¢2 cells that were highly resistant to MTX (500 UM), one
clone 500.8.4, was selected for use, based on its high-titer virus production (106-
10' MTX'CFU/ml). Southern blot analysis of this cell line indicates the presence
of multiple integrated provirus copies, as evidenced both by the smear of
fragments obtained after cleavage of the DNA with enzymes that yield bands
indicative of unique integrations (Fig. 2, lanes 6 and 7), and also by the intensity
of the band generated by cleavage of the DNA with Xba, which cleaves once in
each LTR (Fig. 2, lane 3) compared to a single-copy control (Fig. 2, lane 2). In
addition, comparison of the Xba-digested DNA with the original Zip-DHFR'
plasmid DNA also indicated that the proviral sequences were transmitted intact
to the ¢2 cells (not shown).
In addition to yielding a titer of 106-10' MTX' CFU/ml on 3T3 cells selected
in the presence of 0.25 AM MTX, 500.8.4 also yielded titers of 5 x 102 MTX
CFU/ml on 3T3 cells selected in 100 AM MTX (i.e., 400 times the normal
selection concentration). Southern blot analysis ofinfected 3T3 cells in all cases
confirmed that the Zip-DHFR' sequences were transmitted intact to cells, andWILLIAMS ET AL .
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FIGURE 3.
￿
Southern blot analysis of Xba I-digested genomic DNA isolated from pooled
bone marrow or spleen of transplant recipients engrafted with ZIP-DIFR'-infected bone
marrow cells and treated with MTX. Lane 1, uninfected bone marrow cell DNA; 2, 3T3 cell
DNA containing a single copy of ZIP-DHFR'; 3, infected bone marrow cell DNA (pooled
from four animals); 4-6, infected spleen DNAs from three separate mice. Endogenous murine
DHFR bandsare as noted; the transferred DHFR'gene is seen as an additional 2.7 kb band
in lanes2-6 (arrow) .
FIGURE 2. Southern blot analysis of 02 producer
500.8.4 . Lanes 1-4 ; Xba digests . Lane 1, 10 ug un-
infected 3T3 DNA; lane 2, 10 jug DNA from 3T3
cells infected with a low multiplicity of Zip-DHFR'
virus and selected in 0.25 uM MTX; lane 3, 10ug
500.8.4 DNA; lane 4, 1 ug 500.8.4 DNA; lanes 3-7,
Eco RI digests; lane 5, 10 ug uninfected 3T3DNA;
lane 6, 10 ug 500.8.4 DNA; lane 7, 1 ug 500.8.4
DNA. See Fig . I for map of construct. Xba cleaves
once in each long terminal repeat ; Eco RI does not
cleave in the proviral genome .Arrowdenotesproviral
band.
northern analysis demonstrated expression of the expected 2 .'7 kb DHFR-
containing viralRNA transcript (data not known) .
Detection of Proviral Sequences in Recipients Transplanted with DHFR-Infected
Bane Marrow Cells . Freshly explanted bone marrow cells from CBA/J male
e were infected with Zip-DHFR' and transplanted into lethally irradiated
described in the Materials and Methods . Similarly, a number of
recipients were transplanted with bone marrow cells infected by DHFR-neo (1),
a construct that confers G418 resistance upon cells in culture yet does not
transmit an intact or functional copy of the DHFR gene . To establish the
efficiency of gene transfer in these experiments, DNA was isolated from the
bonemarrowand spleen cells ofanumber ofrecipients 8 wk after transplantation
zed by the method ofSouthern (Fig. 3) .
In each spleen and bone marrow DNA sample from the recipients transplanted
with infected cells and selected with MTX, proviral sequences of the expected
size could be detected (Fig . 3, lanes 3-6) . It was difficult to ascertain the efficiency214
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TABLE I
Survival ofRecipients Transplanted with Bone Marrow Cells
Infected with DHFR' or Neo Virus andSubsequently
Treated withMTXfor 4 wk
atocrit determinations . Blood was ob-
tained by tail vein bleeds and spun in
microhematocrit tubes with heparin .
Mean ± SD . Numbers of determina-
tions : week 1, n = 8;week 2, n = 8;week
3.5, n = 6, except neo-treated, n = 1 ;
week 8, DHFR'-untreated n = 6,
DHFR'-treated n = 4 . (9) Transplanted
with DHFR' containing bone marrow ;
no MTX treatment . (A) Transplanted
with DHFR' containing bone marrow ;
treated with MTX. (p) Transplanted
with neo-containing bone marrow,
treated with MTX.
of gene transfer with much accuracy, due to the fact that much less DNA
representing single copy proviral sequences was loaded in comparison with the
spleen and bone marrow DNA samples (compare Fig. 3 lane 2 to lanes 3-6) .
Nevertheless, based on the relative intensity of bands representing the endoge-
nous DHFR sequences and the proviral sequences in each lane, ^"10-20% of
bone marrow and spleen cells appeared to harbor the proviral sequences . This
level of infection is consistent with our previous experience with the particular
infection protocol used here (D . A. Williams, unpublished data) .
Effects ofMTX Treatment of Transplant Recipients .
￿
As expected from pilot
experiments, the treatment of recipients transplanted with bone marrow cells
infected with the neo gene-containing virus with MTX resulted in 100% mor-
tality by 3.5 wk . In contrast, the presence of the DHFR' gene was associated
with asignificant increase in survival (Table 1) . Treatment oftransplant recipients
with MTX was associated with dramatic changes in hematological parameters,
both in control animals as well as in those transplanted with cells infected with
Zip-DHFR' (Fig . 4) . While transplantation ofDHFR' or neo-containing cells into
recipients followed by no drug treatment resulted in a mild anemia that resolved
by 3 .5 wk after transplantation, MTX treatment of recipients transplanted with
marrow infected either with the DHFR' or neo constructs led to a dramatic fall
in peripheral hematocrit to a plateau at 2 wk after transplant . During the period
between 2 and 3.5 wk all mice transplanted with neo gene-containing virus-
infected marrow died, with premorbid hematocrits of 5-6% . In recipients
containing DHFR' gene-containing virus-infected marrow, significantly higher
Group infected with : treatent Survival
DHFR'gene - 12/12
DHFR'gene + 11/12
Neo gene (control) + 0/12
FIGURE 4 . Results of peripheral hem-FIGURE 5 .
￿
(a)Bone marrow cellularity and (b and c) progenitor content of mice treated with
MTX . Numbersabove bars represent number of animalsexamined .
(p < 0.01) hematocrits were observed at 1, 2, and 3.5 wk after transplant and
normal hematocrits were obtained by 8wk in spite of continuedMTX treatment
during this entire period . This apparent protective effect of the DHFRr gene
was also reflected in peripheral bloodabsolute granulocyte and absolute lympho-
nts, and spleen cellularity (data not shown), and in the bone marrow
cellularity of these mice (Fig . 5a). Mild bone marrow hypoplasia in transplanted
mice not treated with MTX largely recovered by 3.5 wk after transplant. In
mice transplanted with neo gene-containing virus-infected bone marrow that
were treated with MTX, severe hypoplasia at 2 wk worsened during the period
imal death between 2 and 3.5 wk . Animals receivingbone marrow contain-
DHFRr gene and treated with MTX were less hypoppaasic at 2 wk and
marrow cellularity recovered to near that of untreated mice by 3.5 wk .
Additional experiments carried out revealed significant changes in the progen-
itor compartment ofbone marrow (Fig . 5, b and c) in these animals as well . Bone
marrow progenitors are stem cells with limited self-renewal and restricted differ-
ion capacity that can be cultured in vitro. Both granulocyte-macrophage
(CFU-GM) (7) and erythroid (BFU-E) (8) progenitors in mice containing the
DHFRr gene were intermediate between control treated and untreated mice . In
he neo gene and treated with MTX, a relative increase in the
concentration of CFU-GM progenitors (44 per 105 compared to 9 per 1
untreated mice) (Fig . 5b) led to maintenance of the total number of these
progenitors per two hind limbs (one animal) at 2 wk after transplant . However,
with continued MTX treatment, the number of these progenitors was nearly
exhausted by 3 .5 wk after transplant (Fig. 5c) . The increase in CFU-GM
concentration during MTX treatment has been previously reported (11). In
contrast, animals in which theDHFRr gene was present showed little increase in
the concentration ofCFU-GM progenitors (17 per 105 vs . 9 per 105 in untreated
(Fig . 5b), and by 3.5 wk the total number ofCFU-GM in these mice was
four times that of control, treated mice (1,900 CFU-GM per two hind limbs vs .
WILLIAMS ET AL.
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400 CFU-GM per hind limb) (Fig . 5 c) . We observed similar results in the number
of erythroid progenitors (BFU-E) (data not shown) .
Discussion
We have constructed a recombinant retroviral genome encoding a MTX-
resistant DHFR enzyme (DHFR'), and shown its ability to efficiently confer a
high level of MTX-resistance upon cells in vitro. To generate cell lines producing
Zip-DHFR` virus at sufficient titers for bone marrow infection studies, a protocol
was developed for generating ,(i2 virus producing cell lines containing multiple
integrated Zip-DHFR`proviral copies . +G2 cells possessing multiple proviral copies
could be selected in very high levels ofMTX and yielded cell lines producing
uniformly high viral titers . A similar strategy for generating high titer producer
cell lines has recently been described (12) .
In addition to demonstrating the use of theDHFR' virus for generating MTX
resistance in vitro, which has also been reported by others (12), we showed the
ability of Zip-DHFR'-infected bone marrow cells to protect transplant recipients
from otherwise lethal doses of MTX and alter a number of hematological
parameters affected byMTX administration . Whilethesefindings certainlyimply
that the Zip-DHFR' construct can be reasonably well expressed in hematopoietic
cells, the interpretation of these results must be tempered by the fact that the
evidence for expression is indirect and the nature of the cells responsible for the
protective effect unknown. Previous studies in our laboratory and by other
investigators have indicated that a number of standard retroviral constructs show
dramatic differences in their ability to be expressed in cell lines in vitro versus
primary hematopoietic cells (13) . In particular, we have recently reported that
while a Zip-DHFR' construct containing human adenosine deaminase (ADA)
cDNA sequences is efficiently expressed in cultured fibroblasts and B andT cell
lines, only low levels of viral transcript can be detected in cells derived from
infected CFU-S (14) . A number of other investigators have also reported very
low levels of expression of retroviral construction after their transfer to hema-
topoietic cells in vivo (15, 16). In addition, Dick et al . (2) have reported the
decline of expression of viral LTR (long terminal repeat)-promoted constructs
in hematopoietic cells in vivo over time . These data may suggest that the specific
retroviral construct used may be a critical determinant of the capacity of the
integrated proviral sequences to be subsequently expressed in more mature cells
derived from the infected stem cells . Taken together, the available data would
suggest that it is unlikely that the Zip-DHFR' construct is efficiently expressed
in the progeny of infected totipotent hematopoietic stem cells . We suggest that
the protective effect of the Zip-DHFR' virus observed in transplant recipients
may be due to infection and subsequent expression of the provirus in a class of
reasonably short-lived progenitor cells, and may depend upon the unique sensi-
tivity of posttransplant hematopoiesis to chemotherapeutic agents such as MTX .
Such sensitivity toMTX hasalso recently been observed in dogs in the immediate
posttransplant period (17). The results demonstrated in the experiments here
could therefore result from protection mediated during a critical time after
transplantation, and do not necessarily imply permanent reconstitution of treated
animals with MTX' bone marrow cells. Clearly, experiments such as thoseWILLIAMS ET AL.
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presented here will need to be extended to include the analysis of transplant
recipients after longer periods of reconstitution. Most important, however, will
be the development of vectors that result in the efficient and stable expression
of inserted sequences in hematopoietic cells derived from transduced stem cells
capable of long-term engraftment of recipients.
In general, the availability of retrovirus vectors encoding MTX resistance may
allow the development of protocols for the selection in vivo of transduced
hematopoietic stem cells and/or stem cell progeny. This method would be of
value when the efficiency of gene transfer is limited by low-titer recombinant
producers. In addition, the ability to systemically treat animals receiving the
DHFRr gene in vivo will allow study of the effects of selective pressure on the
number and function of hematopoietic stem and progenitor cells and the possible
development of more aggressive chemotherapeutic protocols involving MTX.
Finally, several fatal inherited diseases are manifest primarily in bone marrow-
derived cells, and as such are likely candidates for somatic gene correction using
retrovirus-mediated gene transfer (18). Because success in somatic gene therapy
may depend on introducing a foreign gene in a self-renewing stem cell that will
then be exposed to selective pressure in the patient, such basic data could be of
critical importance in the successful use of gene transfer for the treatment of
bone marrow diseases.
Summary
To develop a highly efficient means for generating methotrexate resistant
(MTX') hematopoietic cells in vivo, a recombinant retroviral genome was con-
structed that encodes a MTX' dihydrofolate reductase (DHFRr) . Cell lines
producing high titers of virus capable of transmitting the DHFR gene were
generated and used to infect mammalian cells in vitro. Analysis of infected
fibroblasts indicated that the DHFR' gene was transmitted intact and conferred
a high level of MTX' upon cells. Based on these findings, DHFR'-containing
virus was used to infect murine bone marrow cells in vitro. Following infection,
the transduced cells were introduced into lethally irradiated recipients via bone
marrow transplantation techniques. The presence of the proviral sequences in
cells of the spleen and bone marrow of engrafted recipients was associated with
significantly increased survival of mice treated with otherwise lethal doses of
MTX .
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